Demand for menopause hormone therapy is on the rise – but training gaps remain for doctors

Public interest in menopause hormone therapy (MHT) has surged significantly as open conversations about midlife health become more common and clinical data regarding its safety has evolved. Many women are now seeking treatments like transdermal estradiol and progesterone to manage symptoms, leading to supply chain challenges and temporary rationing by health agencies. While early 2000s research initially discouraged widespread use due to perceived health risks, modern long-term studies have provided more reassuring evidence, shifting clinical guidelines toward personalized care. Despite this renewed demand, the medical field faces a persistent hurdle in the form of inadequate professional training. Many practitioners who entered the workforce during the period when MHT prescriptions were discouraged lack the necessary experience to manage these treatments effectively. Consequently, there is an urgent need to bridge the gap between patient expectations and the current level of clinical expertise to ensure women receive appropriate, evidence-based support.

The growing demand for menopause treatment highlights a critical disconnect between modern clinical understanding and the current state of medical education and supply chain stability.